Phio Pharmaceuticals Corp. - Common Stock (PHIO)

Around 34% foresee a pullback, while 13% are uncertain due to the stock's volatility.

Phio Pharmaceuticals stock drops 39.1% after announcing a $3.19 million direct offering and concurrent private placement.

Phio Pharma just reported results for the first quarter of 2024.

CEO Robert Bitterman highlighted the potential of Phio’s proprietary INTASYL RNAi technology, which targets proteins that hinder the body’s immune response to cancer.

Phio Pharmaceuticals reports promising Phase 1b trial results for PH-762, showing complete tumor clearance in two patients with no significant adverse effects.

Shares of Rumble Inc.

PHIO stock results show that Phio Pharma missed analyst estimates for earnings per share the second quarter of 2024.

Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!